BRISBANE, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the Company will hold an Analyst Day on Tuesday, September 30, 2014, from 9:00 a.m. to 11:15 a.m. ET (6:00 a.m. to 8:15 a.m. PT).
During this meeting, members of Hyperion's leadership team will provide a business update and development progress.
To access the live webcast and subsequent archived recording, please visit Hyperion's website at http://investors.hyperiontx.com/events.cfm. Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available beginning 24 hours after the live presentation until October 30, 2014.
About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases. The company's first commercial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is currently being marketed in the United States. The company also owns worldwide rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it markets in the U.S. The compound is also marketed internationally through business partners. In addition, the company is developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. For more information, please visit www.hyperiontx.com.
CONTACT: Myesha Edwards Corporate Communications and Investor Relations (650) 745-7829
Source:Hyperion Therapeutics, Inc.